74 research outputs found
Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: a pooled analysis acrossphase III and longâterm extension studies
Objective:
The risk of cardiovascular disease (CVD) is higher in patients with psoriatic arthritis (PsA) compared to the general population. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Because tofacitinib increases circulating lipid levels in some patients, we evaluated CVD risk factors and major adverse cardiovascular events (MACE) in patients with active PsA receiving tofacitinib 5 or 10 mg twice daily plus conventional synthetic diseaseâmodifying antirheumatic drugs.
Methods:
Data were pooled from 2 phase III studies (Efficacy and Safety of Tofacitinib in Psoriatic Arthritis [OPAL Broaden] and Tofacitinib in Patients with Psoriatic Arthritis With Inadequate Response to TNF Inhibitors [OPAL Beyond]) and 1 ongoing longâterm extension (OpenâLabel Extension Study of Tofacitinib in Psoriatic Arthritis [OPAL Balance], data cutoff January 2017; database not locked). Outcomes included fasting lipid levels, blood pressure, hypertensionârelated adverse events (AEs; including hypertension, high blood pressure, and increased blood pressure), and MACE.
Results:
Overall, 783 tofacitinibâtreated patients were included. Percentage increases from baseline in lowâdensity lipoprotein cholesterol (LDLâc) and highâdensity lipoprotein cholesterol (HDLâc) levels ranged from 9% to 14% for tofacitinib 5 mg and 10 mg at 3 and 6 months; no meaningful changes in LDLâc:HDLâc or total cholesterol:HDLâc ratios were observed. Blood pressure remained stable for 24 months. Fiftyâeight patients (7.4%) had hypertensionârelated AEs; none were fatal (incidence rate [IR] per 100 patientâyears 4.81 [95% confidence interval (95% CI) 3.65â6.22]). Five patients (0.6%) had MACE (IR 0.24 [95% CI 0.05â0.70]); 2 were fatal.
Conclusion:
Serum lipid level increases at month 3 following tofacitinib treatment in PsA were consistent with observations in rheumatoid arthritis and psoriasis. The IR of hypertensionârelated AEs and MACE was low; longâterm followâup is ongoing
Introduction to skin aging
YesCutaneous science has seen considerable development in the last 25 years, in part due to the
-Omics revolution, and the appreciation that this organ is hardwired into the bodyâs key neuroimmuno-
endocrine axes. Moreover, there is greater appreciation of how stratification of skin
disorders will permit more targeted and more effective treatments. Against this has been how
the remarkable extension in the average human life-span, though in the West at least, this
parallels worrying increases in lifestyle-associated conditions like diabetes, skin cancer etc. These
demographic trends bring greater urgency to finding clinical solutions for numerous age-related
deficits in skin function caused by extrinsic and intrinsic factors. Mechanisms for aging skin
include the actions of reactive oxygen species (ROS), mtDNA mutations, and telomere
shortening, as well as hormonal changes.
We have also significantly improved our understanding of how to harness the skinâs considerable
regenerative capacity e.g., via its remarkable investment of stem cell subpopulations. In this way we
hope to develop new strategies to selectively target the skinâs capacity to undergo optimal wound
repair and regeneration. Here, the unsung hero of the skin regenerative power may be the humble
hair follicle, replete with its compliment of epithelial, mesenchymal, neural and other stem cells. This
review introduces the topic of human skin aging, with a focus on how maintenance of function in
this complex multi-cell type organ is key for retaining quality of life into old age
Effect of crystalline versus protein-bound lysine on plasma amino acids in exercising horses
73 Crude protein from forage correlates with nitrogen retention and nitrogen status in adult horses
Effect of dietary protein intake on nitrogen balance, plasma amino acids, and fecal bacteria communities in exercising horses
- âŠ